Establishing gene therapies as a relevant, recognized and accessible therapeutic category

Published: 10 November 2021
Interview
Tay Salimullah

Tay Salimullah is Vice President, Global Head of Value and Access, currently building a 21st century integrated access function to transform rare diseases through gene therapies. He oversees translational access, gene pricing and contracting, geneconomics, real-world data, and public policy. He has diverse global market access, pricing, and commercial experience across biopharmaceuticals, consultancy, social sector and private equity. Since joining Novartis in 2013, Tay has led strategic and operational teams across various divisions in Pharma, Region Europe, Oncology, Cell and Gene Therapies, and Group Global Health with a focus on inspiring associates to think early and differently about patient access and reimbursement. Before Novartis, Tay spent over a decade with Pfizer where he held positions of increasing responsibility within commercial, market access, and strategy development. In 2009 Tay completed his Global Health Fellowship: in-field healthcare systems experience in Malawi. He has also worked for a private investment group to incubate healthcare access across Asia. He has lived and worked in Europe, Asia, Africa and the USA, and is passionate about breakthrough thinking to transform global patient access.

Read now